ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial.

ABSTRACT:

Background

The benefit of immediate antiretroviral therapy (ART) at CD4 >500 cells/μL was established in the Strategic Timing of Antiretroviral Treatment (START) study. The benefits and risks of immediate ART in participants with low pretreatment viremia, including virologic suppressors, were further assessed.

Setting

Randomized prospective international study.

Methods

START participants with enrollment viremia <3000 c/mL were included. We compared clinical outcomes (grade 4 adverse events, hospitalizations, or death), plasma viremia, CD4 counts, and changes in biomarkers in immediate versus deferred ART groups.

Results

Participants (N = 1134 including 93 with viremia ≤50 c/mL) had a median age of 37 years, 40% were women, and median CD4 was 713 cells/µL. Ninet

SUBMITTER: Sereti I 

PROVIDER: S-EPMC6607914 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature